Screening for Biological Response Modifiers: Methods and Rationale

James E. Talmadge (u. a.)

ISBN 10: 1461296242 / ISBN 13: 9781461296249

Published by Springer, 2011

About this Item

Screening for Biological Response Modifiers: Methods and Rationale | James E. Talmadge (u. a.) | Taschenbuch | xiv | Englisch | 2011 | Springer | EAN 9781461296249 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.

Seller Inventory # 105629362

Bibliographic Details

• Title: Screening for Biological Response Modifiers: Methods and Rationale
• Publisher: Springer
• Publication Date: 2011
• Language: English
• ISBN 10: 1461296242
• ISBN 13: 9781461296249
• Binding: Taschenbuch
• Condition: Neu
• Dimensions: 235W x 155H x 12D millimeters 235 millimeters width by 155 millimeters height by 12 millimeters depth
• Weight: 330 grams
• Seller catalogs:
  • Bücher

About this title

Synopsis

The observation in the 1950s that nitrogen mustard and other toxic chemicals could induce antitumor responses in patients with refractory lymphoma initiated a massive search for active chemotherapeutic agents. The initial observations stimulated a search for new chemotherapeutic agents which might have increased antitumor activity with less toxicity for normal tissues. To aid in the search for these new chemicals and to attempt to distinguish among the many toxic chemicals which might be candidates for clinical studies, the National Cancer Institute, the pharmaceutical industry, and the cancer research laboratories of most Western nations developed systems for "screening" drugs for antitumor activity. Perhaps the most extensive screening program was established by the National Cancer Institute (1). This screening program has evolved over the last two decades, an evolution which has been repeatedly reviewed (2-5). Various screening programs in use have examined over 500,000 compounds as potential anticancer agents. From these, there are now approximately forty anticancer drugs in clinical use. The utiliy of these compounds and their toxicities have been reviewed on many occasions. It is now apparent that more active and less toxic anticancer drugs are needed. It is also clear that the current screening programs are identifying compounds with similar levels of activity and with continuing moderate to severe toxicity (6).